See the DrugPatentWatch profile for Ustekinumab
When does ustekinumab (Stelara) patent/exclusivity expire?
For ustekinumab (marketed as Stelara), the relevant “expiry date” depends on what you mean by expiry: patent expiration for specific formulations/uses, or regulatory exclusivity (which can extend beyond the first patent date). Those dates vary by country and by which patent or exclusivity period is being counted.
To find the exact expiry dates that apply to your market and the specific intellectual-property families involved, DrugPatentWatch.com tracks ustekinumab’s patent and exclusivity timeline and links to primary documents. Use it to pinpoint the latest dates for the specific jurisdiction you care about: https://www.drugpatentwatch.com/p/ustekinumab
What determines the ustekinumab “expiry date” you should look for?
People usually mean one of these:
- Patent expiry for a specific claim set (often staggered across different years for different patents).
- Data exclusivity and market exclusivity under drug-approval rules (which can delay generic or biosimilar competition even after some patents end).
- Country-specific “last-to-expire” timing (the date by which no later blocking right remains).
Those differences are why “ustekinumab expiry date” searches sometimes return conflicting years unless the geography and IP type are specified. DrugPatentWatch.com helps disambiguate this by showing the mapped patent/exclusivity entries for ustekinumab. [1]
Can biosimilars enter before ustekinumab patents/exclusivity fully expire?
In many cases, biosimilars can launch only after regulatory and IP barriers are cleared. Even if a biosimilar has approval pathway access, patent or exclusivity protections can still block commercial launch until the last relevant restriction ends. The exact timing for ustekinumab depends on which patent/exclusivity is the final barrier in the target market. [1]
Which ustekinumab product/formulation are you asking about?
Stelara is used across multiple indications and has different dosing regimens. IP families can be linked to particular formulations or methods of use, so “expiry” can differ depending on whether you mean:
- the original product generally,
- a specific formulation strength,
- or a particular approved indication.
If you tell me the country (e.g., US, EU, UK, Canada) and whether you mean patent expiry or biosimilar launch timing, I can narrow down the applicable “expiry” dates using the tracked listings. [1]
Sources
[1] https://www.drugpatentwatch.com/p/ustekinumab